论文部分内容阅读
目前已知血管紧张肽原酶—血管紧张素系统(renin—angiotensin system)的功能障碍是心血管病及肾脏疾病的关键因素,其中由血管紧张素转化酶(ACE)催化血管紧张素Ⅰ蛋白水解产生血管紧张素Ⅱ(AⅡ)的过程又在血压控制中起重要作用。尽管ACE酶抑制剂是一类高血压治疗药物,但AⅡ受体特异性拮抗剂可能会更有针对性地被用于治疗高血压病。事实上,一种AⅡ受体强效拮抗剂沙拉新(saralasin)已有明显的药理作用,只是至今尚无一个可以开发为药物的天
It has been known that dysfunction of the renin-angiotensin system is a key factor in cardiovascular and renal diseases, in which angiotensin-converting enzyme (ACE) catalyzes the hydrolysis of angiotensin I The process of producing angiotensin II (AII) plays an important role in blood pressure control. Although ACE inhibitors are a class of drugs for the treatment of hypertension, AII receptor-specific antagonists may be more specifically targeted for the treatment of hypertension. In fact, salalasin, a potent antagonist of the AII receptor, has been shown to have significant pharmacological effects, but no one has ever been developed as a drug